The presentation will take place at day 3, session 11, from 14:00 to 14:20 in Palacio de Congresos De
Valencia, Valencia, Spain.

About Isconova

Isconova AB is a leading international vaccine adjuvant company. Isconova has deep knowledge of
vaccine systems, and the company develops novel vaccines together with partners in the human and
veterinary markets. The first vaccine using Isconova’s Matrix technology was launched in the
veterinary market in 2006. In the human vaccine market, a number of vaccines are under
development with Isconova’s third generation nano-particle, Matrix-M™. The Company is
headquartered in Uppsala, Sweden. For more information, visit www.isconova.com